Adagene (ADAG) Stock Price, News & Analysis

Company Overview

Adagene (NASDAQ: ADAG) is a clinical-stage biotechnology company committed to the discovery and development of next-generation antibody therapeutics. Leveraging its proprietary AI-driven discovery platforms, Adagene focuses on designing allosteric modulators and agonistic antibodies that can precisely tune immune pathways. The company’s core technology integrates machine learning algorithms with a unique “SMART” display system to identify novel binding modalities and functional activities beyond those achievable with conventional antibody approaches.

Adagene’s research programs span immuno-oncology, autoimmune and inflammatory diseases. Its pipeline includes bispecific and multispecific antibodies engineered to engage multiple targets or immune cell subsets simultaneously. These candidates are designed to improve tumor selectivity, enhance T-cell activation and reduce off-target effects. In parallel, Adagene is advancing antibody modulators that selectively dampen pathogenic immune responses in chronic inflammatory conditions.

The company operates R&D facilities in China and maintains a growing presence in the United States, enabling seamless collaboration across global research hubs. Adagene has established strategic partnerships with leading pharmaceutical companies to accelerate preclinical validation and advance key assets toward clinical trials. Its multidisciplinary teams of computational biologists, protein engineers and immunologists work in concert to translate cutting-edge science into therapeutic candidates.

Founded in 2017 by a group of seasoned immunology and antibody engineering experts, Adagene is led by an executive team with deep experience in biotech innovation and drug development. Headquartered in Suzhou with operations in Beijing and a U.S. subsidiary in Boston, the company is guided by a board of directors and scientific advisors who have steered multiple biologics through regulatory approvals. Adagene’s mission is to harness advanced antibody modalities to address unmet medical needs and bring transformative therapies to patients worldwide.

Key Stats

• Today's Range: $1.82 to $1.97
• 50-Day Range: $1.43 to $2.09
• 52-Week Range: $1.33 to $3.58
• Volume: 43,484 shs
• Average Volume: 63,688 shs
• Market Capitalization: $91.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Moderate Buy

Adagene Stock Analysis - MarketRank™

Adagene scored higher than 39% of companies evaluated by MarketBeat, and ranked 655th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adagene has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Adagene has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adagene are expected to decrease in the coming year, from ($0.60) to ($0.76) per share.

Price to Book Value per Share Ratio

Adagene has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.25% of the float of Adagene has been sold short.

Short Interest Ratio / Days to Cover

Adagene has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adagene has recently increased by 28.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adagene does not currently pay a dividend.

Dividend Growth

Adagene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.25% of the float of Adagene has been sold short.

Short Interest Ratio / Days to Cover

Adagene has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adagene has recently increased by 28.12%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.20

News Sentiment

Adagene has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Adagene this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adagene insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.51% of the stock of Adagene is held by institutions.

ADAG Stock Analysis - Frequently Asked Questions

How have ADAG shares performed this year?

Adagene's stock was trading at $1.99 at the beginning of the year. Since then, ADAG stock has decreased by 2.0% and is now trading at $1.95.

When did Adagene IPO?

Adagene (ADAG) raised $133 million in an initial public offering on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager.

How do I buy shares of Adagene?

Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adagene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adagene investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Today: 7/07/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADAG
• CIK: 1818838
• Web: www.adagene.com
• Phone: 86-512-8777-3632
• Fax: N/A
• Employees: 260
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +321.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 2.30
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $100 thousand
• Price / Sales: 895.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.14 per share
• Price / Book: 1.67

Miscellaneous

• Outstanding Shares: 47,110,000
• Free Float: 37,123,000
• Market Cap: $89.51 million
• Optionable: Not Optionable
• Beta: 0.74